Introduction to Novel Drug Delivery Systems

Le résumé fourni par la source

Conventional drug delivery systems are referred to as classical drug delivery approaches, mainly aimed at immediate drug release for rapid absorption, without making a deliberate attempt to solve the challenges ahead (e.g., repeated dosing, fluctuations, and systemic side effects) or create an added value (e.g., controlling the release rate). Such restrictions opened the arena for Novel Drug Delivery Systems (NDDSs), with major competitive advantages, to be raised. NDDSs is a broad term to describe all the formulations , dosage forms , devices , techniques , technologies , and approaches that are used intentionally to exert temporal and/or spatial control over drug delivery in the host body. It has been decades since the emergence of the NDDS concept and since then, numerous types of NDDSs have been introduced and developed. In this chapter, after a brief review of their historical background, an attempt has been made to present a comprehensive classification of what is known today as NDDSs (mainly including nanocarriers, microcarriers, cell-based carriers, and drug delivery devices). Then, following a Why-How-What Framework, the “Why” of developing NDDSs will first be discussed, looking at the positive impact they can have on each phase of pharmacokinetic phases (LADME: Liberation, Absorption, Distribution, Metabolism, and Excretion). Then, “How” to overcome the biological barriers facing NDDSs to achieve an optimal drug release at the right time in the right place, and the formulation considerations that should be taken into account to achieve this goal will be explained. Finally, “What” therapeutics can be potentially delivered by NDDSs, to combat the diseases, will be addressed.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.